Efficacy and safety of epicutaneous immunotherapy for severe egg allergy
Phase 2
- Conditions
- Food allergy
- Registration Number
- JPRN-UMIN000022348
- Lead Sponsor
- ational Hospital Organization Mie National Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Allergy to soy and milk 2) Large change in intake levels of egg before 3 months of the trial 3) Complication or past history of heart, liver and kidney diseases 4) Uncontrolled asthma or atopic dermatitis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dose threshold in oral egg challenge after 24 weeks of treatment
- Secondary Outcome Measures
Name Time Method Safety: local reaction, systemic immediate-type allergic reaction and other